TNM 001
Alternative Names: TNM-001Latest Information Update: 04 Jul 2024
At a glance
- Originator Trinomab Biotech
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Membrane fusion protein inhibitors; Viral envelope protein inhibitors; Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Respiratory syncytial virus infections
Most Recent Events
- 30 Jun 2024 Zhuhai Trinomab Pharmaceutical completes the Phase-I/II clinical trials in Respiratory syncytial virus infections (In volunteers) in China (IM) (NCT05630573)
- 06 Oct 2023 Trinomab Biotech plans a phase IIb/III trial for Respiratory syncytial virus infections (Prevention, In neonates, In infants) in China (IM) in October 2023 (NCT06083623)
- 25 Oct 2022 Phase-I/II clinical trials in Respiratory syncytial virus infections (In volunteers) in China (IM) (NCT05630573)